CAMBRIDGE, Mass. – November 28, 2011 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced it will give corporate presentations at two upcoming investor conferences. John Knopf, Ph.D., Chief Executive Officer, will provide a corporate presentation at the Piper Jaffray 23rd Annual Health Care Conference and Steven Ertel, Senior Vice President, Corporate Development, will present at the Oppenheimer 22nd Annual Healthcare Conference. The details for each presentation are shown below.
Piper Jaffray 23rd Annual Health Care Conference
Date: Wednesday, November 30, 2011
Location: The New York Palace, New York City
Time: 9:30 to 9:50 AM (EST)
Oppenheimer 22nd Annual Healthcare Conference
Date: Tuesday, December 13, 2011
Location: The Waldorf-Astoria, New York City
Time: 9:40 to 9:55 AM (EST)
About Acceleron
Acceleron is a privately-held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel protein therapeutics for orphan diseases and cancer. Acceleron’s scientific approach takes advantage of its unique insight to discover first-in-class therapies based on the TGF-β protein superfamily. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to advance its therapeutic programs rapidly and efficiently. The investors in Acceleron include Advanced Technology Ventures, Alkermes, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For further information on Acceleron, please visit www.acceleronpharma.com.
CONTACT:
Acceleron Pharma:
Steven Ertel, 617-649-9234
Senior Vice President, Corporate Development
Maureen L. Suda (Media)
Suda Communications LLC, 585-387-9248
# # #